Rallybio Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected closing of the merger with Avenzo Therapeutics | 31 Dec 2026 |
| Avenzo presentation of preliminary updated data from the AVENTINE-1 and BEACON-1 Phase 1 studies | 31 Dec 2026 |
| Avenzo presentation of preliminary updated data from the ORION-1 Phase 1 study (AVZO-023 + fulvestrant) | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Progress of RLYB116 Phase 2 Proof of Concept Study QuarterlyTarget: Initiation of Phase 2 study in immune PTR in 2H 2026
Progress of RLYB212 Phase 2 Trial QuarterlyTarget: Continued patient enrollment on track
Watch Items
- Stockholder approval of the Avenzo Therapeutics merger and related proposalsTrigger: Stockholder vote at the upcoming Special MeetingAction: Monitor SEC filings for the definitive proxy statement and voting results
- Effectiveness of the Form S-4 Registration Statement for the Avenzo mergerTrigger: SEC declaration of effectivenessAction: Track SEC EDGAR filings for the S-4 registration statement and subsequent amendments
- Distribution of Rallybio's pre-closing net cash to stockholdersTrigger: Declaration and deposit of net cash with the transfer agent prior to merger closingAction: Verify the final net cash calculation and distribution terms
Research as of 20 Jun 2026